FDA PMA FDA Class 2 Approved 🇺🇸 United States

Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus

PMA: P020011 · Supplement: S002 · Decision Sep 17, 2010
Classifications
1
FEI Numbers
10
Registration Numbers
10

Basic Information

Device Name
Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus
Trade Name
VERSANT & APTIMA HCV RNA QUALITATIVE ASSAY
PMA Number
P020011
Supplement Number
S002
Device Class
FDA Class 2
Product Code
MZP
Generic Name
Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
Regulation Number
866.3170
Medical Specialty
Microbiology
Advisory Committee
Microbiology
Decision
Approved
Decision Code
APPR
Decision Date
September 17, 2010
Date Received
February 23, 2010
Supplement Type
135 Review Track For 30-Day Notice
Supplement Reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR A CHANGE IN QUALITY CONTROL SPECIFICATIONS FOR THE HCV CALIBRATORS.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MZP Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus